\BOOKMARK [1][-]{section.0.1}{Problemafgr\346nsning}{}% 1
\BOOKMARK [2][-]{subsection.0.1.1}{Problemformulering}{section.0.1}% 2
\BOOKMARK [0][-]{chapter.1}{Beskrivelse og tekniske karakteristika for teknologien \(TEC\)}{}% 3
\BOOKMARK [1][-]{section.1.1}{Form\345l}{chapter.1}% 4
\BOOKMARK [1][-]{section.1.2}{HTA sp\370rgsm\345l}{chapter.1}% 5
\BOOKMARK [1][-]{section.1.3}{Metode HTAcore}{chapter.1}% 6
\BOOKMARK [1][-]{section.1.4}{Teknologiens egenskaber}{chapter.1}% 7
\BOOKMARK [2][-]{subsection.1.4.1}{Fokusomr\345de for QST}{section.1.4}% 8
\BOOKMARK [2][-]{subsection.1.4.2}{Unders\370gelse af PPT, TS og CPM}{section.1.4}% 9
\BOOKMARK [1][-]{section.1.5}{Teknologiens begr\346nsninger}{chapter.1}% 10
\BOOKMARK [2][-]{subsection.1.5.1}{Begr\346nsende faktorer ved benyttelse af QST}{section.1.5}% 11
\BOOKMARK [1][-]{section.1.6}{Sammenligning med nuv\346rende metoder}{chapter.1}% 12
\BOOKMARK [2][-]{subsection.1.6.1}{Samarbejde mellem QST og klinisk vurdering}{section.1.6}% 13
\BOOKMARK [1][-]{section.1.7}{Delkonklusion}{chapter.1}% 14
\BOOKMARK [0][-]{chapter.2}{Sikkerhed \(SAF\)}{}% 15
\BOOKMARK [1][-]{section.2.1}{Form\345l}{chapter.2}% 16
\BOOKMARK [1][-]{section.2.2}{HTA sp\370rgsm\345l}{chapter.2}% 17
\BOOKMARK [1][-]{section.2.3}{Metode HTAcore}{chapter.2}% 18
\BOOKMARK [1][-]{section.2.4}{Patientsikkerhed}{chapter.2}% 19
\BOOKMARK [2][-]{subsection.2.4.1}{Sikkerhedsm\346ssige risici for patienter}{section.2.4}% 20
\BOOKMARK [1][-]{section.2.5}{Sikkerhedsforanstaltninger}{chapter.2}% 21
\BOOKMARK [2][-]{subsection.2.5.1}{Sikkerhedsforanstaltninger ved anvendelse af QST}{section.2.5}% 22
\BOOKMARK [1][-]{section.2.6}{Delkonklusion}{chapter.2}% 23
\BOOKMARK [0][-]{section*.6}{Litteratur}{}% 24
